The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets
Open accessAbstract
By virtue of their large number, widespread distribution and important roles in cell physiology and biochemistry, G-protein-coupled receptors (GPCR) play multiple important roles in clinical medicine. Here, we focus on 3 areas that subsume much of the recent work in this aspect of GPCR biology: (1) monogenic diseases of GPCR; (2) genetic variants of GPCR; and (3) clinically useful pharmacological agonists and antagonists of GPCR. Diseases involving mutations of GPCR are rare, occurring in <1/1000 people, but disorders in which antibodies are directed against GPCR are more common. Genetic variants, especially single nucleotide polymorphisms (SNPs), show substantial heterogeneity in frequency among different GPCRs but have not been evaluated for some GPCR. Many therapeutic agonists and antagonists target GPCR and show inter-subject variability in terms of efficacy and toxicity. For most of those agents, it remains an open question whether genetic variation in primary sequence of the GPCR is an important contributor to such inter-subject variability, although this is an active area of investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
G Protein–Coupled Receptor Rhodopsin
Palczewski, K. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142743 · Cited by 764
The Dopamine D2 Receptor: New Surprises from an Old Friend
Bonci, A., & Hopf, F. W. (2005) · Neuron · doi:10.1016/j.neuron.2005.07.015 · Cited by 115
Cited by
Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
Xu, S., Olenyuk, B. Z., Okamoto, C. T., & Hamm-Alvarez, S. F. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.041 · Cited by 467
How reliable are G-protein-coupled receptor antibodies?
Michel, M. C., Wieland, T., & Tsujimoto, G. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-009-0395-y · Cited by 306
Self-citationRole of cholesterol in the function and organization of G-protein coupled receptors
Pucadyil, T. J., & Chattopadhyay, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.02.002 · Cited by 296
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
Metadata
- Authors
- Insel, P. A., Tang, C.-M., Hahntow, I., & Michel, M. C.
- Venue
- Biochimica et Biophysica Acta (BBA) - Biomembranes
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 1768
- Issue
- 4
- Pages
- 994-1005
- ISSN
- 0005-2736 (ISSN-L)
- OpenAlex
- W2079104124
- Cited by
- 178
- References
- 4
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. https://app.cochat.ai/papers/10.1016/j.bbamem.2006.09.029
- The paper
- Insel, P. A., Tang, C.-M., Hahntow, I., & Michel, M. C. (2007). Impact of GPCRs in clinical medicine: Monogenic diseases, genetic variants and drug targets. Biochimica et Biophysica Acta (BBA) - Biomembranes. https://doi.org/10.1016/j.bbamem.2006.09.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.